MedTrace Logo

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

NCT06041035 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2023-09-18

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

Conditions

Interventions

DRUG

QLS31905

Administered as an intravenous infusion.

DRUG

Nab paclitaxel

125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

DRUG

Gemcitabine

1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

DRUG

Oxaliplatin

85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

DRUG

Capecitabine

1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.

DRUG

Cisplatin

25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-10-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041035 on ClinicalTrials.gov